Ayaz-ul-Haque

Technomark Investment Management Ltd. (TIM) is inactive since 2009. Formerly known as Technomark Medical Ventures, TIM is the venture capital arm and a subsidiary of Technomark Consulting Services Ltd., a consulting firm specialized in the pharmaceutical and biotechnology sectors, and the European branch of the US-based Technomark Group USA LLC, headquartered in Research Triangle Park, North Carolina. The group has additional offices in Mumbai, India and in Nanjing, China. The activities of the Technomark group include corporate finance, venture capital and management consulting focused on outsourcing in the pharmaceutical domain. Their clients are large pharmaceutical corporations, contract research organizations, contract manufacturing organizations, investment banks and public entities. Technomark's European branch operates since 1987 in London. TIM originated in 2000 with the backing of Lloyds TSB Development Capital Ltd., the venture capital arm of Lloyds TSB Group plc (LSE: LLOY; NYSE: LYG). The current firm was formally established in 2005 when the group was reorganized. TIM manages a private equity fund focused on the life sciences.

Technomark Investment Management Ltd. (TIM) is inactive since 2009. Formerly known as Technomark Medical Ventures, TIM is the venture capital arm and a subsidiary of Technomark Consulting Services Ltd., a consulting firm specialized in the pharmaceutical and biotechnology sectors, and the European branch of the US-based Technomark Group USA LLC, headquartered in Research Triangle Park, North Carolina. The group has additional offices in Mumbai, India and in Nanjing, China. The activities of the Technomark group include corporate finance, venture capital and management consulting focused on outsourcing in the pharmaceutical domain. Their clients are large pharmaceutical corporations, contract research organizations, contract manufacturing organizations, investment banks and public entities. Technomark's European branch operates since 1987 in London. TIM originated in 2000 with the backing of Lloyds TSB Development Capital Ltd., the venture capital arm of Lloyds TSB Group plc (LSE: LLOY; NYSE: LYG). The current firm was formally established in 2005 when the group was reorganized. TIM manages a private equity fund focused on the life sciences.